The concomitant use of galcanezumab and any other medications is not contraindicated, according to the Emgality Summary of Product Characteristics (SmPC).1

Please check the SmPC of all, in combination administered medications.

We excluded patients who are taking, or are expected to take, therapeutic antibodies, for example adalimumab, infliximab, trastuzumab, bevacizumab, during the galcanezumab phase 3 studies from participating.2-5 We do not have data about the safety or efficacy of galcanezumab when concomitantly administered with therapeutic antibodies.

As a humanised Immunoglobulin G4 (IgG4) monoclonal antibody, galcanezumab is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.1

As such, it is not expected to

• inhibit metabolic or induce enzymatic pathways
• be metabolized by the cytochrome P450 families of drug-metabolizing enzymes, and
• produce any active metabolites.5-7

No drug interaction studies were conducted. No pharmacokinetic drug interactions are expected based on the characteristics of galcanezumab.1

There are no known interactions for galcanezumab, drug-drug or otherwise.5

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.